When should continuous subcutaneous insulin infusion (CSII) be considered in pediatric patients with diabetes mellitus (DM)?

Updated: Sep 27, 2021
  • Author: Romesh Khardori, MD, PhD, FACP; Chief Editor: George T Griffing, MD  more...
  • Print

Pediatric patients

  • CSII is indicated for pediatric patients with elevated hemoglobin A1C (HbA1C) levels on injection therapy; frequent, severe hypoglycemia; widely fluctuating glucose levels; a treatment regimen that compromises lifestyle; and microvascular complications and/or risk factors for macrovascular complications.

  • Ideal pediatric candidates are those with motivated families who are committed to monitoring blood glucose 4 or more times per day and have a working understanding of basic diabetes management.

  • Patient age and duration of diabetes should not be factors in determining the transition from injections to CSII.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!